BridgeBio Pharma (BBIO) Stock Overview
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BBIO Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
BridgeBio Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.03 |
| 52 Week High | US$57.49 |
| 52 Week Low | US$21.72 |
| Beta | 1.36 |
| 1 Month Change | 6.88% |
| 3 Month Change | 18.32% |
| 1 Year Change | 110.12% |
| 3 Year Change | 461.53% |
| 5 Year Change | 36.86% |
| Change since IPO | 99.75% |
Recent News & Updates
Recent updates
BridgeBio Pharma: Betting Big On Rare Disease Catalysts
Aug 19
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 09
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now
Apr 28BridgeBio: Early Signs Point To Blockbuster Revenues
Apr 22BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
Feb 07BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Jan 15BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jan 12BridgeBio: Next Chapter Begins After Attruby Approval
Nov 24BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be
Nov 19BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
Aug 17BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Shareholder Returns
| BBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.4% | -1.5% |
| 1Y | 110.1% | -0.7% | 14.4% |
Return vs Industry: BBIO exceeded the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: BBIO exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BBIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 728 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio Pharma, Inc. Fundamentals Summary
| BBIO fundamental statistics | |
|---|---|
| Market cap | US$10.83b |
| Earnings (TTM) | -US$776.41m |
| Revenue (TTM) | US$235.81m |
Is BBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIO income statement (TTM) | |
|---|---|
| Revenue | US$235.81m |
| Cost of Revenue | US$8.97m |
| Gross Profit | US$226.84m |
| Other Expenses | US$1.00b |
| Earnings | -US$776.41m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.06 |
| Gross Margin | 96.19% |
| Net Profit Margin | -329.25% |
| Debt/Equity Ratio | -104.0% |
How did BBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 12:56 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 30 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |